Pre-Test A New Look at a Seasoned Solution: Characteristics of LAI Antipsychotics for BD-I (Module 2) Pre-Test Which of the following is the first 2-month LAI antipsychotic approved/indicated for both treatment of schizophrenia and the maintenance treatment of bipolar I disorder Aripiprazole monohydrate Olanzapine Paliperidone palmitate Risperidone microspheres Unsure Recently published data from a study evaluating the safety, tolerability, and plasma concentrations associated with a 2-month vs 1-month LAI formulation of aripiprazole demonstrated which of the following Higher rates of discontinuation due to adverse events with the 2-month formulation Higher rates of all-cause discontinuations with the 2-month formulation Improved efficacy with the 2-month formulation vs the 1-month formulation Similar aripiprazole concentrations with the 2-month formulation vs the 1-month formulation Unsure Please now rate your ability to use currently available therapies to manage bipolar disorder. Excellent Very Good Good Fair Poor
